Showing 1 - 10 of 38
Persistent link: https://www.econbiz.de/10011341663
Expected shortfall (ES) is a popular risk measure and plays an important role in risk and portfolio management. Recently, change-point detection of risk measures has been attracting much attention in finance. Based on the self-normalized CUSUM statistic in Fan, Glynn and Pelger (2018) and the...
Persistent link: https://www.econbiz.de/10013206368
Persistent link: https://www.econbiz.de/10011685315
Persistent link: https://www.econbiz.de/10014266004
Persistent link: https://www.econbiz.de/10014555725
In this article we develop a tractable procedure for testing strict stationarity in a double autoregressive model and formulate the problem as testing if the top Lyapunov exponent is negative. Without strict stationarity assumption, we construct a consistent estimator of the associated top...
Persistent link: https://www.econbiz.de/10012433198
We examine the high volume return premium across countries as a test of the investor recognition hypothesis. Our cross-country tests are consistent with the hypothesis in that we find the magnitude of the premium is associated with market characteristics that relate to the importance of a...
Persistent link: https://www.econbiz.de/10012739262
Performance-based contracts (PBC) have become ubiquitous in industries ranging from aerospace and defense to computer support services. Despite advantages of paying for performance under PBC that have been highlighted in many previous studies, the more traditional Transaction-based Contracts...
Persistent link: https://www.econbiz.de/10012935116
We introduce a supply chain network equilibrium model with differentiated products, in which firms compete on product quantities and quality. We then extend the model to include a strict quota or tariff. We establish the equivalence between the model with a strict quota and that with a tariff,...
Persistent link: https://www.econbiz.de/10012866185
In this paper, we present a pharmaceutical supply chain network model with outsourcing under price and quality competition, in both equilibrium and dynamic versions. We consider a pharmaceutical firm that is engaged in determining the optimal pharmaceutical flows associated with its supply chain...
Persistent link: https://www.econbiz.de/10012978415